Hartness Named to Bryn Pharma Board of Directors
19 December 2022 - - US-based pharmaceutical company Bryn Pharma LLC has appointed Jeff Hartness to its board of directors, the company said.

Hartness joins a group of senior directors focused on commercialization.

Hartness brings more than 25 years of leadership and success in creating and executing go-to-market strategies in the healthcare space to Bryn's Board.

He has launched dozens of products in disease states including small molecules, specialty/biologics, devices, OTCs and generics.

He is currently a member of Bausch Health company's Global Executive Committee as senior vice president and Head of Market Access, Commercial Operations, Policy and government Affairs.

In this role, he focuses on the commercialization strategy of pricing, contracting and the creation of patient access to Bausch Health products, as well as the distribution of those products throughout the healthcare system.

Prior to joining Bausch Health, Hartness spent 15 years at Sanofi in various leadership roles, including Product Launch Execution and as the Head of Pharmacy Benefit Managers, Employers and Specialty business.

Hartness currently serves on the board of directors for Corganics, a privately held clinical cannabinoid life sciences company based in Dallas, Texas.

Bryn Pharma, established in 2017, is a privately held pharmaceutical company founded by patients for patients.

Bryn is focused on positively disrupting the existing market for epinephrine autoinjectors by delivering an accessible, easy-to-use alternative that better meets the needs of patients.

Bryn Pharma seeks to provide this growing population at risk for anaphylaxis with A Better Way to be prepared for a life-threatening allergic reaction.